Microsatellite Instability: Clinical Trials

5 trials for Microsatellite Instability, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 12Completed 2

Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Prolgolimab - Colorectal Cancer
Phase 2CompletedBlokhin's Russian Cancer Research Center302022-03-312026-04-27
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
temozolomide (induction),, pembrolizumab (treatment) - Colorectal Neoplasms, Microsatellite Instability
Phase 2CompletedIFOM ETS - The AIRC Institute of Molecular Oncology1072019-01-232026-03-03
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center42018-03-072024-11-27
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Nivolumab - Carcinoma, Renal Cell, Head and Neck Neoplasm
Phase 2CompletedUNICANCER2692017-06-162024-02-28
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
MK-3475, INCB024360 - Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Phase 1 / Phase 2CompletedIncyte Corporation4442014-07-172022-02-14

Narrower conditions

Colorectal Neoplasms (3)  ·  Carcinoma, Renal Cell (2)  ·  Head and Neck Neoplasms (2)  ·  Carcinoma, Hepatocellular (1)  ·  Colonic Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)  ·  Penile Neoplasms (1)  ·  Rectal Neoplasms (1)  ·  Skin Neoplasms (1)

Broader conditions

Genomic Instability (5)  ·  Neoplasms (5)  ·  Neoplasms by Site (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Digestive System Diseases (4)  ·  Digestive System Neoplasms (4)  ·  Gastrointestinal Diseases (4)  ·  Gastrointestinal Neoplasms (4)  ·  Colonic Diseases (3)  ·  Intestinal Diseases (3)  ·  Intestinal Neoplasms (3)  ·  Rectal Diseases (3)  ·  Adenocarcinoma (2)  ·  Carcinoma (2)

Interventions

pembrolizumab (2)  ·  Neoadjuvant Therapy (1)  ·  Nivolumab (1)  ·  Temozolomide (1)  ·  Therapeutics (1)  ·  bintrafusp alfa protein, human (1)  ·  epacadostat (1)

Sponsors

Blokhin's Russian Cancer Research Center (1)  ·  IFOM ETS - The AIRC Institute of Molecular Oncology (1)  ·  Incyte Corporation (1)  ·  M.D. Anderson Cancer Center (1)  ·  UNICANCER (1)

Countries

United States (2)  ·  France (1)  ·  Italy (1)  ·  Russia (1)

Top investigators

Mark Jones, MD (1)  ·  Salvatore Siena, MD (1)  ·  Silvia Marsoni, MD (1)  ·  Van K Morris, MD (1)

Results publications

PMID 33109741, PMID 35522273, PMID 35791694, PMID 39594133, PMID 41370727

NIH funding

2016 (1), 2018 (1)